TheranosticTrials.org

Clinical Trial · NCT07691775

A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors

Overview

This Phase I/II clinical study, titled "A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors", aims to evaluate the safety and diagnostic performance of F18 FBPA PET/CT imaging in subjects with solid tumors. The primary objective is to evaluate the safety and establish the optimal screening conditions (including dose, timing and image quality) of F18 FBPA PET/CT in patients with solid tumors.

Sponsor

Unknown Organization

Phase

Phase 1/2

ClinicalTrials.gov

NCT07691775

Drug / Compound

FBPA

Isotope(s):
Target(s):
  • LAT1/LAT2
Ligand Class: Small Molecules

Eligibility

Inclusion

  • At least one measurable lesion identified on prior imaging evaluation, assessed by RECIST version 1.1.

Exclusion

  • History of radiation therapy within 3 months prior to the screening visit.
  • Body weight \> 80 kg at screening.
  • History of renal impairments, including nephrolithiasis, nephrotic syndrome, or hematuria, and/or other severe renal conditions in the opinion of the investigator.
  • History of phenylketonuria.